{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:09:33Z","timestamp":1782630573053,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and study aims:<\/jats:bold> The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> We included 51 patients who received escitalopram for irritable bowel syndrome (n = 26), functional heartburn (n = 10), globus sensation (n = 10) or combined disorders (n = 5). We used an irritable bowel syndrome-severity scoring system IBS-SSS), GerdQ questionnaire and Glasgow Edinburg Throat Scale (GETS) to assess disease severity change before and after treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median age was 33 years (25th- 75th percentiles: 29\u201347), and 26 (50.98%) were males. Forty-one patients experienced side effects (80.39%), but most side effects were mild. The most common side effects were drowsiness\/fatigue\/dizziness (54.9%), xerostomia (23.53%), nausea\/vomiting (21.57%) and weight gain (17.65%). IBS-SSS was 375 (255\u2013430) and 90 (58\u2013205) before and after treatment, respectively (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). GerdQ score was 12 (10\u201313) before treatment and 7 (6\u201310) after treatment (<jats:italic>p<\/jats:italic> = 0.001). GETS score before treatment was 32.5 (21\u201346) and after treatment became 22 (13\u201331) (<jats:italic>p<\/jats:italic> = 0.002). Thirty-five patients refused to take the medications, and seven patients discontinued the medication. Possible causes of the poor compliance were fear of the medications and not being convinced of taking psychiatric medications for functional disorders (n = 15).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Escitalopram could be a safe and effective treatment for functional gastrointestinal disorders. Targeting and managing factors leading to poor compliance could further improve the treatment outcome.<\/jats:p>","DOI":"10.3389\/fphar.2023.1131354","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:43:14Z","timestamp":1684759394000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders"],"prefix":"10.3389","volume":"14","author":[{"given":"Saad S.","family":"Alkhowaiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani H.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala F.","family":"Almarzouqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadah K.","family":"Alonazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq M.","family":"Alhawassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"AlRasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.15537\/smj.2020.2.24844","article-title":"Prevalence of gastroesophageal reflux in diabetic patients at a tertiary hospital in Central Saudi Arabia","volume":"41","author":"AlTassan","year":"2020","journal-title":"Saudi Med. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2036.2006.02772.x","article-title":"Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: A double-blind, placebo-controlled study","volume":"23","author":"Broekaert","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/ajg.2015.132","article-title":"Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients","volume":"110","author":"Cassell","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1742-1241.2011.02746.x","article-title":"Effectiveness of interventions to improve antidepressant medication adherence: A systematic review","volume":"65","author":"Chong","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0022-3999(94)00104-d","article-title":"Globus pharyngis: Development of a symptom assessment scale","volume":"39","author":"Deary","year":"1995","journal-title":"J. Psychosom. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"00223","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/nmo.12251","article-title":"Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease","volume":"26","author":"Forcelini","year":"2014","journal-title":"Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/cgh.2003.50032","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/jcm6110099","article-title":"Rome criteria and a diagnostic approach to irritable bowel syndrome","volume":"6","author":"Lacy","year":"2017","journal-title":"J. Clin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cgh.2009.09.008","article-title":"Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome","volume":"8","author":"Ladabaum","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-244X-13-65","article-title":"Follow up of patients who start treatment with antidepressants: Treatment satisfaction, treatment compliance, efficacy and safety","volume":"13","author":"L\u00f3pez-Torres","year":"2013","journal-title":"BMC Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13632","DOI":"10.1111\/nmo.13632","article-title":"Effect of citalopram on esophageal motility in healthy subjects-Implications for reflux episodes, dysphagia, and globus","volume":"31","author":"Manolakis","year":"2019","journal-title":"Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.gastro.2015.04.020","article-title":"Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study","volume":"149","author":"Talley","year":"2015","journal-title":"Gastroenterology"},{"key":"B16","first-page":"678","article-title":"Treatment of functional GI disorders with psychotropic medicines: A review of evidence with a practical approach","volume":"2","author":"Thiwan","year":"2006","journal-title":"Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11894-018-0664-3","article-title":"Psychotropics, antidepressants, and visceral analgesics in functional gastrointestinal disorders","volume":"20","author":"T\u00f6rnblom","year":"2018","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1756283X11409279","article-title":"Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus","volume":"4","author":"Viazis","year":"2011","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fpsyt.2018.00659","article-title":"Antidepressants vs. Placebo for the treatment of functional gastrointestinal disorders in adults: A systematic review and meta-analysis","volume":"9","author":"Xiong","year":"","journal-title":"Front. psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fpsyt.2018.00122","article-title":"Illness perception of patients with functional gastrointestinal disorders","volume":"9","author":"Xiong","year":"","journal-title":"Front. psychiatry"},{"key":"B22","first-page":"725","article-title":"Update on functional heartburn","volume":"13","author":"Yamasaki","year":"2017","journal-title":"Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1131354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:43:19Z","timestamp":1684759399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1131354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":22,"alternative-id":["10.3389\/fphar.2023.1131354"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1131354","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"article-number":"1131354"}}